临床笔记丨危及生命的药物相互作用

2015-01-15 佚名 用药助手

1、伊曲康唑+特非那定 特非那定说明书“禁忌与三唑类抗真菌药(如酮康唑、伊曲康唑等)、与某些大环内酯类抗生素如(克拉霉素、红霉素、竹桃霉素等)以及严重损伤肝脏功能的其他药物合用。”伊曲康唑说明书“已报道当使用本品超过推荐剂量时,与环孢菌素A、阿司咪唑和特非那丁有相互作用。这些药物若与本品同服时,应减少剂量。”  文献依据:SFDA药品说明书范本2、卡马西平+地尔硫卓&nbs

1、伊曲康唑+特非那定 


特非那定说明书“禁忌与三唑类抗真菌药(如酮康唑、伊曲康唑等)、与某些大环内酯类抗生素如(克拉霉素、红霉素、竹桃霉素等)以及严重损伤肝脏功能的其他药物合用。”伊曲康唑说明书“已报道当使用本品超过推荐剂量时,与环孢菌素A、阿司咪唑和特非那丁有相互作用。这些药物若与本品同服时,应减少剂量。”
 
文献依据:SFDA药品说明书范本

2、卡马西平+地尔硫卓 

地尔硫卓缓释片说明书“本品与卡马西平合用后,一些病例中可使卡马西平的血药浓度增高40-72%而导致毒性。” 

文献依据:SFDA药品说明书范本

3、克拉霉素+麦角胺 

麦角胺咖啡因逾量可引起严重中毒,急性中毒症状为精神错乱、共济失调、惊厥、手足灰白发冷、感觉障碍,甚至因昏迷与呼吸麻痹而死亡。克拉霉素“与其他大环内酯类抗生素相似,本品会升高需要经过细胞色素P450系统代谢的药物的血清浓度(如阿司咪唑、华法林、麦角生物碱、三唑仑、咪达唑仑、环孢素、奥美拉唑、雷尼替丁、苯妥因、溴隐亭、阿芬他尼、海索比妥、丙吡胺、洛伐他汀、他克莫司等)。”
 
文献依据:SFDA药品说明书范本

4、环磷酰胺+吲哚美辛 

NSAID可增加抗利尿激素的分泌,两药联用可能导致急性水中毒,必要时进行监测。其他非甾体抗炎药也可能发生相似的相互作用。 

文献依据:汤光.药物相互作用速查手册[M].北京:化学工业出版社,2005.233~234.

5、依那普利+别嘌醇 

别嘌醇与血管紧张素转换酶抑制药类降压药和氨氯地平等合用,可引起史-约综合征(Stevens-Johnson syndrome)和皮疹等过敏反应。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.937~938.

6、洛伐他汀+吉非罗齐 

吉非罗齐片说明书“氯贝丁酸衍生物与羟甲戊二酰辅酶A还原酶抑制剂,如洛伐他汀等合用治疗高脂血症,将增加两者严重肌肉毒性发生的危险,可引起肌痛、横纹肌溶解、血肌酸磷酸激酶增高等肌病,应尽量避免联合使用。”
文献依据:SFDA药品说明书范本

7、甲氨蝶呤+萘普生 

甲氨蝶呤“与部分非甾体类抗炎药联用,有突发严重甚至致命性骨髓抑制和胃肠毒性的报道。”萘普生“可升高甲氨蝶呤的血药浓度,从而增强其毒性(白细胞减少、血小板减少、贫血、中毒性肾损害和粘膜溃疡形成)。” 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.342~344,1341~1343.

8、对乙酰氨基酚+华法林 

华法林个体差异较大,治疗期间应严密观察病情,并依据凝血酶原时间INR值调整用量。增强本品抗凝作用的药有:阿司匹林、水杨酸钠、胰高血糖素、奎尼丁、吲哚美辛、保泰松、奎宁、利尿酸、甲磺丁脲、甲硝唑、别嘌呤醇、红霉素、氯霉素、某些氨基糖苷类抗生素、头孢菌素类、苯碘达隆、西米替丁、氯贝丁酯、右旋甲状腺素、对乙酰氨基酚等。

文献依据:SFDA药品说明书范本

9、胺碘酮+地高辛 

胺碘酮“增加血清地高辛浓度,亦可能增高其它洋地黄制剂的浓度达中毒水平,当开始用本品时洋地黄类药应停药或减少50%,如合用应仔细监测其血清中药浓度。本品有加强洋地黄类药对窦房结及房室结的抑制作用。” 

文献依据:SFDA药品说明书范本

10、卡马西平+红霉素 

卡马西平缓释片“烟酰胺、抗抑郁药、大环内酯类抗生素、异烟肼、西咪替丁等药物均可使本品血浓度升高,可出现毒性反应。”
文献依据:药品说明书范本

11、西咪替丁+美沙酮 

西咪替丁可使卡马西平、美沙酮、他克林的血药浓度升高,有导致药物过量的危险。
文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.711~714.

12、环丙沙星+茶碱 

环丙沙星与茶碱类合用时可能由于与细胞色素P450结合部位的竞争性抑制,导致茶碱类的肝消除明显减少,血消除半衰期(t1/2β)延长,血药浓度升高,出现茶碱中毒症状,如恶心、呕吐、震颤、不安、激动、抽搐、心悸等,故合用时应测定茶碱类血药浓度和调整剂量。
文献依据:SFDA药品说明书范本

13、雷尼替丁+麻醉椒 
 
资料缺

14、环孢素+地尔硫卓 

环孢素与雌激素、雄激素、西咪替丁、地尔硫卓、红霉素、酮康唑等合用,可增加本品的血浆浓度。因而可能使本品的肝、肾毒性增加。故与上述各药合用时须慎重,应监测患者的肝、肾功能及本品的血药浓度。 

文献依据:SFDA药品说明书范本

15、地高辛+阿普唑仑 

阿普唑仑“与地高辛合用,可增加地高辛血药浓度而致中毒。”
文献依据:SFDA药品说明书范本

16、地高辛+红霉素 

红霉素“与地高辛合用会增加后者的血药浓度,甚至达到中毒水平。建议要进行临床与心电图监测,必要时要调整地高辛的用量。” 

文献依据:SFDA药品说明书范本

17、地高辛+伊曲康唑 

伊曲康唑“已报道本品与华法林和地高辛有相互作用。因此这些药物若与本品同服时,应减少剂量。”伊曲康唑(斯皮仁诺)“在使用本品治疗期间需监测血浆浓度、药物作用及副作用的药物,当与伊曲康唑合用时,必要时应当减量:地高辛(通过抑制P-糖蛋白)。”

文献依据:SFDA药品说明书范本

18、地高辛+奎尼丁 

地高辛“与奎尼丁同用,可使本品血药浓度提高约一倍,提高程度与奎尼丁用量相关,甚至可达到中毒浓度,即使停用地高辛,其血药浓度仍继续上升,这是奎尼丁从组织结合处置换出地高辛,减少其分布容积之故。两药合用时应酌减地高辛用量1/2~1/3。” 

文献依据:SFDA药品说明书范本

19、布洛芬+锂盐 

锂盐的治疗指数低,治疗量和中毒量较接近。碳酸锂“与非甾体抗炎药〔如布洛芬、吲哚美辛)、乙醇和大多数抗精神病药合用,可使血锂浓度升高,增加锂的毒性。”
文献依据:《中国国家处方集》编委会.中国国家处方集.化学药品与生物制品卷[S].北京:人民军医出版社,2010.963.

20、甲氨蝶呤+复方磺胺甲噁唑 

甲氨蝶呤“与保泰松和磺胺类药物同用后,因与蛋白质结合的竞争,可能会引起本品血清浓度的增高而导致毒性反应的出现。”甲氧苄啶“不宜与抗肿瘤药、2,4-二氨基嘧啶类药物同时应用,也不宜在应用其他叶酸拮抗药物治疗的疗程之间应用本品。因为有产生骨髓再生不良或巨幼红细胞贫血的可能。” 

文献依据:SFDA药品说明书范本

21、美托洛尔+氟西汀 

氟西汀可引起美托洛尔的血药浓度升高,毒性增大,故应注意监测,必要时减少美托洛尔的用量。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.499~502.

22、咪达唑仑+舒芬太尼 

咪达唑仑与芬太尼或舒芬太尼同用,可引起严重呼吸抑制及突然低血压,因而这些药合用时应严密监测血药浓度,并且适当减少剂量。
文献依据:《新编临床用药参考》

23、硝苯地平+镁 

镁剂用于早产治疗时,如与本药合用可引起显著的低血压和神经肌肉阻滞。合用时应密切监测血压。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.577~580.

24、诺氟沙星+茶碱 

诺氟沙星“与茶碱类合用时可能由于与细胞色素P450结合部位的竞争性抑制,导致茶碱类的肝清除明显减少,血消除半衰期(t1/2β)延长,血药浓度升高,出现茶碱中毒症状,如恶心、呕吐、震颤、不安、激动、抽搐、心悸等,故合用时应测定茶碱类血药浓度和调整剂量。”
文献依据:SFDA药品说明书范本

25、苯妥英+胺碘酮 

胺碘酮可以抑制苯妥英肝代谢,升高苯妥英血清浓度,以致产生运动失调、眼球震颤、视觉模糊和双腿无力。需监测病人苯妥英水平,必要时调整其剂量。胺碘酮同其他乙内酰脲类抗惊厥药物同用有类似的相互作用。 

文献依据:汤光.药物相互作用速查手册[M].北京:化学工业出版社,2005.90.

26、苯妥英+氯霉素 

苯妥英钠“与氯霉素、异烟肼、保泰松、磺胺类合用可能降低本品代谢使血药浓度增加,增加本品的毒性。” 

文献依据:SFDA药品说明书范本

27、苯妥英+西咪替丁
西咪替丁“与苯妥英钠或其他乙内酰脲类合用,可能使后者的血药浓度增高,导致苯妥英钠中毒,必须合用时,应在5天后测定苯妥英钠血药浓度以便调整剂量,并注意定期复查周围血象。”
文献依据:SFDA药品说明书范本

28、普萘洛尔+氟西汀 

氟西汀可使普萘洛尔血药浓度升高,毒性增大,故应监测普萘洛尔的毒性反应,必要时减少用量。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.493~496.

29、罗红霉素+地高辛 

罗红霉素与地高辛同用,可清除肠道中能灭活地高辛的菌群,导致体内地高辛降解减少,使地高辛血药浓度升高而发生毒性反应,两者合用时应监测心电图和血清强心苷水平。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.144~145.

30、索他洛尔+地尔硫卓 

索他洛尔与钙通道阻滞药(如维拉帕米、地尔硫卓)合用,两者对房室传导和心室功能的影响有累加作用,合用时可加重传导阻滞,进一步抑制心室功能、降低血压,引起低血压、心动过缓、传导障碍和心力衰竭,应避免合用。 

文献依据:卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团,重庆出版社,2009.478~480.

31、链霉素+泮库溴铵 

链霉素与神经肌肉阻滞剂合用,可加重神经肌肉阻滞作用,导致肌肉软弱、呼吸抑制或呼吸麻痹(呼吸暂停)。 

文献依据:SFDA药品说明书范本

32、布洛芬+芬太尼   

资料缺

33、红霉素+西咪替丁
 
西咪替丁升高红霉素的血浆药物浓度(增加毒性发生的危险,其中包括耳聋)。
文献依据:《国家处方集》929页

34、维拉帕米+普萘洛尔 

与β-受体阻滞剂联合使用, 可增强对房室传导的抑制作用。钙拮抗剂合用,特别是静脉注射维拉帕米,要十分警惕本品对心肌和传导系统的抑制。 

文献依据:SFDA药品说明书范本

35、克拉霉素+麦角胺 

与其他大环内酯类抗生素相似,本品会升高需要经过细胞色素P450系统代谢的药物的血清浓度(如阿司咪唑、华法林、麦角生物碱、三唑仑、咪达唑仑、环孢素、奥美拉唑、雷尼替丁、苯妥因、溴隐亭、阿芬他尼、海索比妥、丙吡胺、洛伐他汀、他克莫司等)。逾量可引起严重中毒,急性中毒症状为精神错乱、共济失调、惊厥、手足灰白发冷、感觉障碍,甚至因昏迷与呼吸麻痹而死亡。 

文献依据:SFDA药品说明书范本

36、噻氯匹定+苯妥英钠 

正在接受苯妥英治疗的病人加用噻氯匹定后,苯妥英血药浓度升高,并产生毒性反应。应当仔细监测苯妥英血药浓度的变化,并注意观察是否有毒性反应出现。噻氯匹定至少抑制两种细胞色素P-450酶系统。已知苯妥英的代谢途径包括细胞色素P-450 2C9/10和细胞色素P-450 2C19。故推测,噻氯匹定可能抑制细胞色素P-450 2C19。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-27 lxyzzj

    药物相互作用经常被医生忽视。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-17 ylz8405
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-15 gongzuozhong

    多谢,收藏了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-15 MedSci客户端网友

    厉害!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1909178, encodeId=be3919091e8d9, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Aug 19 00:35:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14733, encodeId=7a8d14e33b0, content=药物相互作用经常被医生忽视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/woXbIlxICLCNmd2Vff8VnDuwUxlOMbsZib5582RE8Vt2kJ4NicZ9aickjKsiavbFM7iccsBjLXiaACaUeicwS81xKWQnA/132, createdBy=0d1e108758, createdName=lxyzzj, createdTime=Tue Jan 27 01:25:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471505, encodeId=6d0314e1505ef, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585010, encodeId=efa41585010bf, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Sat Jan 17 02:35:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14379, encodeId=d11d143e9ce, content=多谢,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Thu Jan 15 15:34:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14373, encodeId=0d28143e392, content=厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Thu Jan 15 14:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14365, encodeId=5b2614365eb, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.156.**, createdTime=Thu Jan 15 11:58:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-15 116.226.156.**

    有用!

    0

相关资讯

FDA批准帕金森症长效疗法上市

随着老年化社会的进程,医药企业都越来越重视如帕金森症、阿尔兹海默症等神经退行性疾病的研究。然而,限于目前医学界对这类疾病认识水平,这类药物也一直是医药产业界的重灾区。不过,最近艾伯维宣布公司开发的用于治疗晚期帕金森症患者运动波动的药物DUOPA获得FDA的上市批准,这一利好消息无疑对今后生物医药产业界更好地开发这类药物打了一针强心剂。 DUOPA是目前市面上第一种畅销治疗帕金森症患者运动

武田药业与Mersana签订价值3亿美元肿瘤ADC药物研发协议

日本著名医药公司武田制药最近宣布公司已经和肿瘤药物研发公司Mersana Therapeutics公司签订了一项价值达3亿美元的合作研发协议。这一协议是建立在两家公司去年四月份达成的合作关系基础上的。 在此次合作中,双方将开展关于抗体药物偶联技术(ADC)的研究。抗体药物偶联技术是近几年来兴起的一种靶向治疗技术,通过将肿瘤药物和特异性抗体偶联起来,使得药物能够特异性富集到特定病灶部位,这一突破一

Blend再获2100万美元投资助力抗体药物偶联疗法研发

最近,由麻省理工学院科学家创立的生物医药研发公司Blend获得了一项总额为2100万美元的风险投资用于开发抗体药物偶联疗法治疗癌症的早期研究。研究人员希望利用转移性抗体与抗肿瘤药物偶联,从而达到靶向治疗实体瘤疾病的目的。同时,研究人员还采用纳米颗粒技术,保证药物在肿瘤患者体内能够运输到相应位置。利用这笔资金,Blend公司希望能够完成这一疗法的临床前研究。 其实,抗体药物偶联疗法并不是近两年

诺华青光眼药物Travatan(曲伏前列素滴眼液)收获欧盟儿科适应症

眼科护理的全球领导者——诺华旗下眼科单元爱尔康(Alcon)近日宣布,已上市青光眼药物Travatan(曲伏前列素滴眼液,40微克/毫升)收获欧盟儿科适应症。欧盟委员会(EC)已批准Travatan用于青光眼或高眼压症儿科(2月-18岁)患者,降低患者升高的眼内压(IOP)。此前,Travantan的适应症为用于高眼压症或开角型青光眼成人患者降低IOP。 Travatan儿科适应症的获批,意味着

FDA批准美金刚胺/多奈哌齐(Namzaric)组合药剂用于治疗阿尔茨海默氏症

美国食品药品监督管理局(FDA)批准固定剂量复方制剂的盐酸美金刚延长释放制剂(XR)和盐酸多奈哌齐(Namzaric,阿特维斯制药 /Adamas Pharm)治疗中度到重度老年痴呆症,患者接受稳定的两种药物剂量。 美金刚XR(Namenda XR, 阿特维斯制药)是一个由N-甲基-D-天门冬氨酸抑制剂,和多奈哌齐(安理申,辉瑞)一种乙酰胆碱酯酶抑制剂(AChEI)。“在一个胶囊里Namzari

Arrowhead治疗乙肝RNA药物ARC-520临床二期研究再遇阻碍

总部位于加利福尼亚州帕萨迪纳市的生物技术公司Arrowhead是一家以开发RNAi疗法为核心的生物医药公司。众所周知,RNAi被很多人认为是充满不确定性因素的研究领域,机遇与挑战并存。Arrowhead公司现有三种RNAi药物正处于研发过程,其中ARC-520是走的最远的一个项目。此外Arrowhead公司还有治疗癌症的小分子非RNA药物Cyclosert也正处于临床二期研究过程中。然而,最近